Our results indicate that MGMT/RASSF1A/SEPT9 gene promoter methylation panel accurately identifies CRC, irrespective of molecular subtype and may have a better performance than currently available epigenetic-based biomarkers. The gene discussed is MGMT; the disease is colorectal carcinoma.